A T and B cell prophylactic and therapeutic HIV vaccine [...]
SEEK has applied its leading breakthrough technology to the development of FLU-v, the first of a new class of T cell vaccines that are anticipated to be effective against the highly-mutagenic influenza virus. FLU-v has been developed to provide a single vaccination which is effective against all strains of flu virus, including pandemic strains. [...]
BC1036, a novel, non-opioid, non-narcotic treatment based on Theobromine, is currently in late-stage development for the treatment of persistent cough. Persistent cough is defined as a cough lasting for more than 2 weeks after symptoms that lead to the cough having ceased. [...]
SEEK is developing a novel drug that targets and destroys oestrogen receptor positive (ER +) breast cancer cells regardless of whether they are HER 2 Neu positive or negative [...]
SEEK is using its breakthrough technology to develop a new class of T cell vaccine that is effective against Hepatitis B [...]
SEEK is using its breakthrough technology to develop a new class of T cell vaccine that is effective against Hepatitis C [...]
SEEK is using its breakthrough technology to develop a new class of T cell vaccine that is effective against Hepatitis B. The synthetic vaccine will comprise a number of Hepatitis B-immunogenic epitopes [...]
SEEK is applying its breakthrough technology to develop a new class of T cell vaccine that is effective against Rotavirus [...]